U.S. court denies Jazz Pharma bid to revive patents on narcolepsy drug

A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, opening the door for Amneal Pharmaceuticals Inc to launch a generic version of the medicine.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *